Structure and dynamics of dynorphin peptide and its receptor.


Journal

Vitamins and hormones
ISSN: 0083-6729
Titre abrégé: Vitam Horm
Pays: United States
ID NLM: 0413601

Informations de publication

Date de publication:
2019
Historique:
entrez: 19 8 2019
pubmed: 20 8 2019
medline: 27 3 2020
Statut: ppublish

Résumé

Dynorphin is a neuropeptide involved in pain, addiction and mood regulation. It exerts its activity by binding to the kappa opioid receptor (KOP) which belongs to the large family of G protein-coupled receptors. The dynorphin peptide was discovered in 1975, while its receptor was cloned in 1993. This review will describe: (a) the activities and physiological functions of dynorphin and its receptor, (b) early structure-activity relationship studies performed before cloning of the receptor (mostly pharmacological and biophysical studies of peptide analogues), (c) structure-activity relationship studies performed after cloning of the receptor via receptor mutagenesis and the development of recombinant receptor expression systems, (d) structural biology of the opiate receptors culminating in X-ray structures of the four opioid receptors in their inactive state and structures of MOP and KOP receptors in their active state. X-ray and EM structures are combined with NMR data, which gives complementary insight into receptor and peptide dynamics. Molecular modeling greatly benefited from the availability of atomic resolution 3D structures of receptor-ligand complexes and an example of the strategy used to model a dynorphin-KOP receptor complex using NMR data will be described. These achievements have led to a better understanding of the complex dynamics of KOP receptor activation and to the development of new ligands and drugs.

Identifiants

pubmed: 31421700
pii: S0083-6729(19)30042-1
doi: 10.1016/bs.vh.2019.05.006
pii:
doi:

Substances chimiques

Receptors, Opioid 0
dynorphin receptor 0
Dynorphins 74913-18-1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

17-47

Informations de copyright

© 2019 Elsevier Inc. All rights reserved.

Auteurs

Guillaume Ferré (G)

Institut de Pharmacologie et de Biologie Structurale (IPBS, CNRS UPS), Université de Toulouse, Toulouse, France. Electronic address: guillaume.ferre@ipbs.fr.

Georges Czaplicki (G)

Institut de Pharmacologie et de Biologie Structurale (IPBS, CNRS UPS), Université de Toulouse, Toulouse, France.

Pascal Demange (P)

Institut de Pharmacologie et de Biologie Structurale (IPBS, CNRS UPS), Université de Toulouse, Toulouse, France.

Alain Milon (A)

Institut de Pharmacologie et de Biologie Structurale (IPBS, CNRS UPS), Université de Toulouse, Toulouse, France. Electronic address: alain.milon@ipbs.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH